InMed Pharmaceuticals Stock (NASDAQ:INM)


RevenueOwnershipFinancialsChart

Previous Close

$4.14

52W Range

$2.42 - $15.70

50D Avg

$4.94

200D Avg

$5.39

Market Cap

$3.16M

Avg Vol (3M)

$39.30K

Beta

0.71

Div Yield

-

INM Company Profile


InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

13

IPO Date

May 05, 2014

Website

INM Performance


INM Financial Summary


Jun 23Jun 22Jun 21
Revenue$6.56B$1.09M-
Operating Income$-8.18B$-13.70M$-9.92M
Net Income$-7.92B$-23.41M$-10.56M
EBITDA$-7.73B$-13.18M$-9.80M
Basic EPS$-3.24$-41.74$-39.30
Diluted EPS$-3.24$-41.74$-39.30

Fiscal year ends in Jun 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 22Sep 23, 22 | 3:28 PM
Q2 22Feb 15, 22 | 8:18 PM
Q4 21Sep 24, 21 | 3:07 PM

Peer Comparison


TickerCompany
ICUSeaStar Medical Holding Corporation
ZVSAZyVersa Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
GOVXGeoVax Labs, Inc.
BDRXBiodexa Pharmaceuticals Plc
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
TNXPTonix Pharmaceuticals Holding Corp.
IMMXImmix Biopharma, Inc.
ALLRAllarity Therapeutics, Inc.
DRUGBright Minds Biosciences Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
PALIPalisade Bio, Inc.
ATNF180 Life Sciences Corp.